GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Price-to-Operating-Cash-Flow

OCUL (Ocular Therapeutix) Price-to-Operating-Cash-Flow : (As of Dec. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Price-to-Operating-Cash-Flow?

As of today (2024-12-13), Ocular Therapeutix's share price is $8.69. Ocular Therapeutix's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.88. Hence, Ocular Therapeutix's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Ocular Therapeutix's Price-to-Operating-Cash-Flow or its related term are showing as below:

OCUL's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.83
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Ocular Therapeutix's Cash Flow from Operations per share for the three months ended in Sep. 2024 was $-0.22. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.88.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 2.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 13.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 12.70% per year.

During the past 12 years, Ocular Therapeutix's highest 3-Year average Operating Cash Flow per Share Growth Rate was 31.60% per year. The lowest was -7.80% per year. And the median was 14.80% per year.


Ocular Therapeutix Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Ocular Therapeutix's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Price-to-Operating-Cash-Flow Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocular Therapeutix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocular Therapeutix's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Ocular Therapeutix's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Price-to-Operating-Cash-Flow falls into.



Ocular Therapeutix Price-to-Operating-Cash-Flow Calculation

Ocular Therapeutix's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=8.69/-0.875
=

Ocular Therapeutix's Share Price of today is $8.69.
Ocular Therapeutix's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Ocular Therapeutix Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix Business Description

Traded in Other Exchanges
Address
15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730